Tag: LivaNova

LivaNova Reports Third-Quarter 2024 Results

LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. “LivaNova delivered strong revenue and operating income growth in the third quarter” Post this Financial Summary and Highlights(1) Third-quarter revenue of $318.1 million increased 11.2% […]

LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director

LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of Directors, effective March 1, 2024. Makatsaria most recently served as Company Group Chairman at Johnson & […]

LivaNova Reports Second-Quarter 2023 Results

LONDON–(BUSINESS WIRE)– LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights1 Second-quarter revenue of $293.9 million increased 15.6% on a reported basis and increased 16.4% on a constant-currency basis, as compared to the […]

LivaNova Reports First-Quarter 2023 Results

LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights1 First-quarter revenue of $263.4 million increased 9.7 percent on a reported basis and increased 12.7 percent on a constant-currency […]

LivaNova Board of Directors Announce Leadership Changes

LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald has resigned as Chief Executive Officer. Effective immediately, Chair of the Board William A. Kozy is appointed interim CEO to help the executive leadership team maintain the focus on growth and profitability. The […]

LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures

LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM). With FDA clearance, LivaNova initiates the commercial launch of Essenz in the U.S. The Company also recently received approval for […]